HGEN - Humanigen falls after change in late-stage COVID-19 study's main goal

Humanigen (HGEN) drops 8% in premarket on low volume after changing the trial protocol of Phase 3 trial evaluating lenzilumab, an experimental medicine for COVID-19.Primary endpoint for the Phase 3 trial of lenzilumab is now ventilator-free survival through day 28. The prior main goal had been time to recovery, which will now be a secondary point of study.The company didn’t give a precise reason for the changes beyond saying the new goal was “more meaningful” for patients, health-care providers, and payers “given the current standard of care for hospitalized and hypoxic COVID-19 patients”

For further details see:

Humanigen falls after change in late-stage COVID-19 study's main goal